Back to search
Anemia, Hemolytic, Autoimmune
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Anemia, Hemolytic, Autoimmune trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Anemia, Hemolytic, Autoimmune trials you may qualify forThis study will evaluate the safety and efficacy of tafasitamab in adult participants with primary autoimmune blood cell disorders.
This is a parallel-group, Phase 3, double-blind, 2-arm study to investigate the efficacy, safety, PK and PD of oral rilzabrutinib in achieving durable Hb respon…
The goal of this clinical study is to evaluate the safety and efficacy of GT801 injection in adult patients with relapsed/refractory CD19-positive B-cell hemato…
The primary objective of this study is to describe the frequency and characteristics of pregnancy outcomes and maternal complications among participants exposed…
This is an investigator-initiated trial to evaluate the safety and efficacy of universal allogeneic anti-CD19/BCMA CAR T-cells in AIHA who have failed ≥ 3 lines…
This study is intended to explore the efficacy and safety of a second course of ianalumab after experiencing treatment failure in the pivotal Primary Immune Thr…
This phase II trial studies the effect of acalabrutinib in treating autoimmune hemolytic anemia that has come back (relapsed) or has not responded to previous t…
This is a single-arm, open-label, multicenter, ascending dose Phase 1/2 trial evaluating the safety and preliminary efficacy of CTX112 or Zugocabtagene geleucel…